Yahong Pharmaceutical announced that its holding subsidiary Baylink Biosciences Inc has received a letter from the US FDA agreeing to the clinical trial application of APL-2501 independently developed by the company to treat advanced solid tumors. This drug is an anti-CLDN6/9 antibody drug conjugate based on a topoisomerase inhibitor and is intended for advanced solid tumors such as ovarian cancer and non-small cell lung cancer. This approval will not have a significant impact on the company's recent performance.

Zhitongcaijing · 3d ago
Yahong Pharmaceutical announced that its holding subsidiary Baylink Biosciences Inc has received a letter from the US FDA agreeing to the clinical trial application of APL-2501 independently developed by the company to treat advanced solid tumors. This drug is an anti-CLDN6/9 antibody drug conjugate based on a topoisomerase inhibitor and is intended for advanced solid tumors such as ovarian cancer and non-small cell lung cancer. This approval will not have a significant impact on the company's recent performance.